End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.49 JOD | +2.05% | 0.00% | +3.75% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 18.34 | 18.62 | 22.99 | 36 | 28.02 | 22.8 |
Enterprise Value (EV) 1 | 16.45 | 16.93 | 19.3 | 30.36 | 22.59 | 17.49 |
P/E ratio | 5.83 x | 5.59 x | 6.55 x | 9.89 x | 7.94 x | 9.8 x |
Yield | - | 5.1% | 8.26% | 6.6% | 8.47% | 6.88% |
Capitalization / Revenue | 1.3 x | 1.19 x | 1.39 x | 2.17 x | 1.64 x | 1.44 x |
EV / Revenue | 1.16 x | 1.08 x | 1.16 x | 1.83 x | 1.32 x | 1.11 x |
EV / EBITDA | 4.28 x | 3.7 x | 4.14 x | 5.71 x | 4.3 x | 4.45 x |
EV / FCF | -14.1 x | 70.8 x | 9.74 x | 10.4 x | 21.8 x | 10.7 x |
FCF Yield | -7.12% | 1.41% | 10.3% | 9.63% | 4.58% | 9.36% |
Price to Book | 0.84 x | 0.78 x | 0.9 x | 1.28 x | 0.95 x | 0.78 x |
Nbr of stocks (in thousands) | 9,500 | 9,500 | 9,500 | 9,500 | 9,500 | 9,500 |
Reference price 2 | 1.930 | 1.960 | 2.420 | 3.790 | 2.950 | 2.400 |
Announcement Date | 28/03/19 | 19/05/20 | 24/03/22 | 24/03/22 | 12/02/23 | 31/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 14.12 | 15.64 | 16.58 | 16.58 | 17.11 | 15.81 |
EBITDA 1 | 3.843 | 4.575 | 4.666 | 5.321 | 5.258 | 3.927 |
EBIT 1 | 3.501 | 4.11 | 4.187 | 4.422 | 4.204 | 2.839 |
Operating Margin | 24.79% | 26.28% | 25.25% | 26.67% | 24.58% | 17.96% |
Earnings before Tax (EBT) 1 | 3.379 | 3.75 | 4.08 | 4.331 | 4.136 | 2.741 |
Net income 1 | 3.144 | 3.332 | 3.511 | 3.642 | 3.529 | 2.328 |
Net margin | 22.26% | 21.3% | 21.17% | 21.96% | 20.63% | 14.73% |
EPS 2 | 0.3309 | 0.3507 | 0.3695 | 0.3834 | 0.3714 | 0.2450 |
Free Cash Flow 1 | -1.17 | 0.2389 | 1.982 | 2.924 | 1.035 | 1.636 |
FCF margin | -8.29% | 1.53% | 11.95% | 17.63% | 6.05% | 10.35% |
FCF Conversion (EBITDA) | - | 5.22% | 42.48% | 54.94% | 19.69% | 41.67% |
FCF Conversion (Net income) | - | 7.17% | 56.46% | 80.27% | 29.34% | 70.29% |
Dividend per Share | - | 0.1000 | 0.2000 | 0.2500 | 0.2500 | 0.1650 |
Announcement Date | 28/03/19 | 19/05/20 | 24/03/22 | 24/03/22 | 12/02/23 | 31/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 1.89 | 1.69 | 3.69 | 5.65 | 5.44 | 5.31 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -1.17 | 0.24 | 1.98 | 2.92 | 1.04 | 1.64 |
ROE (net income / shareholders' equity) | 15.1% | 14.6% | 13.9% | 13.3% | 12.3% | 7.93% |
ROA (Net income/ Total Assets) | 8.4% | 9.14% | 8.63% | 8.49% | 7.84% | 5.19% |
Assets 1 | 37.42 | 36.46 | 40.7 | 42.91 | 45.02 | 44.87 |
Book Value Per Share 2 | 2.300 | 2.520 | 2.690 | 2.970 | 3.090 | 3.090 |
Cash Flow per Share 2 | 0.4700 | 0.3300 | 0.6000 | 0.7600 | 0.7000 | 0.7600 |
Capex 1 | 3.92 | 1.49 | 0.77 | 1.59 | 0.87 | 0.34 |
Capex / Sales | 27.8% | 9.51% | 4.67% | 9.56% | 5.11% | 2.14% |
Announcement Date | 28/03/19 | 19/05/20 | 24/03/22 | 24/03/22 | 12/02/23 | 31/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+3.75% | 33.39M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- HPIC Stock
- Financials Hayat Pharmaceutical Industries Co. PLC